Genetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• González-Gil C.
• Lopes T.
• Morgades M.
• Fuster-Tormo F.
• Medina C.R.
• Hermosín L.
• González-Martínez T.
• Queipo M.-P.
• González-Campos J.
• Martínez-Sánchez P.
• Díaz-Beya M.
• Coll R.
• Maluquer C.
• Zamora L.
• Artola T.
• Vall-Llovera F.
• Tormo M.
• Torrent A.
• Martínez-Laperche C.
• Gil-Cortés C.
• Barba P.
• Cervera M.
• Ribera J.
• Fernández-Delgado M.
• Ayala R.
• Cladera A.
• Mateos M.C.
• Vidal M.J.
• Feliu J.
• Torres A.
• Azaceta G.
• Calasanz M.J.
• Bigas A.
• Esteller M.
• Orfao A.
• Ribera J.M.
• Genescà E.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible

Keywords

• antineoplastic agent; BRG1 protein; cyclin dependent kinase 6; cyclin dependent kinase inhibitor 1B; DNA methyltransferase 3A; F box/WD repeat containing protein 7; Janus kinase 1; Janus kinase 3; Notch1 receptor; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; protein p53; transcription factor CTCF; transcription factor RUNX1; adult; Article; BCL11B gene; clinical trial (topic); clonal evolution; digital polymerase chain reaction; DNA sequencing; female; gene; gene mutation; genetic profile; genetic variability; genetic variation; heterozygosity; homozygosity; human; leukemia relapse; maintenance therapy; major clinical study; male; minimal residual disease; NR3C1 gene; NT5C2 gene; oncogene K ras; oncogene N ras; PHF6 gene; RPL22 gene; single nucleotide polymorphism; somatic mutation; T cell acute lymphoblastic leukemia